Grid connection delays to two utility scale projects in Australia partially offset raised second-quarter revenue reported by Dutch solar developer Photon Energy Group.
The Amsterdam-based company posted an €869,000 loss for the second quarter, down from a €969,000 reverse a year earlier, and blamed rising interest costs associated with refinancing its latest solar projects in Hungary, as well as the two plants in Leeton, in the Australian state of New South Wales. The Australian sites have a combined generation capacity of 14.6 MW.
Those grid delays, and recruitment as part of a planned expansion drive, partially offset a 16% year-on-year rise in revenue from the sale of electricity, which pushed up the total revenue figure 11%, by the same comparison, to €9.86 million for the April-to-June window.
With Photon reporting it has added around 187 MWp of generation capacity in its core European markets of Hungary, Romania and Poland since December, the company bolstered its finances by issuing 5 million shares in a €7.7 million fundraising exercise.
This content is protected by copyright and may not be reused. If you want to cooperate with us and would like to reuse some of our content, please contact: editors@pv-magazine.com.
By submitting this form you agree to pv magazine using your data for the purposes of publishing your comment.
Your personal data will only be disclosed or otherwise transmitted to third parties for the purposes of spam filtering or if this is necessary for technical maintenance of the website. Any other transfer to third parties will not take place unless this is justified on the basis of applicable data protection regulations or if pv magazine is legally obliged to do so.
You may revoke this consent at any time with effect for the future, in which case your personal data will be deleted immediately. Otherwise, your data will be deleted if pv magazine has processed your request or the purpose of data storage is fulfilled.
Further information on data privacy can be found in our Data Protection Policy.